Website Changes
12/25/2016
First patient enrolled in brain tumor trial combining 9 repurposed drugs - CUSP9v3 project
12/19/2016
Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.
12/13/2016
Medicenna Announces Initiation of Phase 2 Clinical Trial of MDNA55 for the Treatment of Recurrent Glioblastoma
12/13/2016
Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to Israel
12/09/2016
NW Bio Provides Update About Phase 3 Trial Of DCVax®-L for Newly Diagnosed Glioblastoma Multiforme Brain Cancer
12/07/2016
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.
12/07/2016
First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report.
12/07/2016
Take a survey - get $75!
12/01/2016
New edition of the "Brain Tumor Guide for the Newly Diagnosed"
11/30/2016
Israel firm has high hopes for new cancer-busting drug
11/26/2016
SNO 2016 Clinical Highlights
11/26/2016
PCV chemotherapy
11/26/2016
Society for Neuro Oncology annual meeting, Scottsdale Arizona, November 17-20 2016
11/25/2016
Clinical and Pre-Clinical Data on Mustang Bio’s MB-101 (IL13Ra2-specific CAR T cells) for the Treatment of Glioblastoma (GBM) Presented at the 21st Annual Meeting and Education Day of the Society for Neuro-Oncology
11/25/2016
ZIOPHARM Announces Clinical Data on Ad-RTS-hIL-12 Demonstrates Survival Benefits in Patients with Recurrent Brain Cancer
11/24/2016
Dr. Reardon on the KEYNOTE-028 Trial of Pembrolizumab for GBM
11/23/2016
Help Us Better Understand Glioblastoma Multiforme (GBM) Patient Experiences
11/21/2016
Society of Neuro-Oncology Annual Meeting Abstract Now Available Online!
11/21/2016
ImmunoCellular Therapeutics (IMUC) Announces Presentation of Updated ICT-107 Phase 2 Data in GBM
11/21/2016
Tocagen Presents Updated Clinical and Preclinical Data at Scientific Meetings
11/18/2016
Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Four-Year Survival Rates
11/09/2016
DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA
11/09/2016
Musella Foundation Co-payment Assistance Program is now closed to new patients
11/09/2016
New vaccine for brain cancer brings hope to those fighting the disease
11/08/2016
Posttranslational Regulation of O(6)-Methylguanine-DNA Methyltransferase (MGMT) and New Opportunities for Treatment of Brain Cancers.
which delivers brain tumor news and additions
to the website via RSS.